Better, Next-Generation Aptamers
Broader Diversity Without PCR Bias
Raptamers™ are different. Using our proprietary selection process, we generate a much wider diversity of candidates than SELEX. This difference is important when you’re engaged in a diagnostic or drug development process; binding affinity, after all, is only part of the equation in any commercial product. The other factors–stability, pharmacokinetics, half-life, binding site, and so on–are often more important, so it’s beneficial to have a wide range of options early in the process. Eliminating PCR bias is one critical step toward that kind of optionality and make Raptamers™ the ideal solution for developing nucleotide-based commercial products.
Ideal for Commercial Applications
Need Something Special? Contact Us!
But that doesn’t mean we’ve thought of everything; if there is a particular type of functionality you want built into your Raptamer™, give us a call. We may be able to build you a custom library that generates candidates more closely attuned to your particular needs. Talk to one of our scientist to get more information.
No PCR Bias